BiotechTube

UCB0942

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Healthy Japanese and Caucasian Subjects

Conditions

Healthy Japanese and Caucasian Subjects

Trial Timeline

May 5, 2017 → Aug 14, 2017

NCT ID
NCT03168984

About UCB0942

UCB0942 is a phase 1 stage product being developed by UCB for Healthy Japanese and Caucasian Subjects. The current trial status is completed. This product is registered under clinical trial identifier NCT03168984. Target conditions include Healthy Japanese and Caucasian Subjects.

What happened to similar drugs?

20 of 20 similar drugs in Healthy Japanese and Caucasian Subjects were approved

Approved (20) Terminated (1) Active (0)
✅Cholestyramine + Colesevelam HClDaiichi SankyoApproved
✅Cholestyramine + Cholestyramine + TangDaiichi SankyoApproved
✅Olmesartan medoxomil + Irbesartan + ValsartanDaiichi SankyoApproved
✅Perampanel 6 MGEisaiApproved
✅eszopiclone, zolpidem, placeboSumitomo PharmaApproved
✅Listerine Experimental Mouthwash + Colgate Cavity Protection Toothpaste + Listerine Total Care ZeroJohnson & JohnsonApproved
✅Listerine Clinical Solutions Teeth Strength + Listerine Total Care Zero Alcohol Mouthwash + Colgate Cavity Protection ToothpasteJohnson & JohnsonApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT03168984Phase 1Completed
NCT02625090Phase 2Terminated

Competing Products

20 competing products in Healthy Japanese and Caucasian Subjects

See all competitors
ProductCompanyStageHype Score
AZD0837AstraZenecaPhase 1
29
ValsartanNovartisPhase 1
29
CSL112 + PlaceboCSLPhase 1
29
UT-15CUnited TherapeuticsPhase 1
26
VNA-318 + PlaceboBiotrialPhase 1
19
Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + PlaceboTrevenaPhase 1
19
TRV130 + Moxifloxacin + PlaceboTrevenaPhase 1
19
Radiolabeled TRV130TrevenaPhase 1
19
TRV130A + Dextrose in WaterTrevenaPhase 1
19
TRV734TrevenaPhase 1
19
ALT02 + EU-licensed Herceptin + US-licensed HerceptinAlteogenPhase 1
29
ENZ215 + EU Sourced Prolia + US Sourced ProliaAlkem LaboratoriesPhase 1
29
KPL-404Kiniksa PharmaceuticalsPhase 1
23
MORF-057 + Placebo for MORF-057Eli LillyPhase 1
29
Propranolol + PseudoephedrineEli LillyPre-clinical
26
LY2157299Eli LillyPhase 1
29
Lasmiditan + PlaceboEli LillyPhase 1
29
LY3015014 + PlaceboEli LillyPhase 1
29
LOXO-783Eli LillyPhase 1
29
LY2541546 - IV + LY2541546 - SC + PlaceboEli LillyPhase 1
29